1,250 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,250 shares of the medical research company’s stock, valued at approximately $246,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Forsta AP Fonden grew its holdings in shares of Charles River Laboratories International by 11.6% during the third quarter. Forsta AP Fonden now owns 10,600 shares of the medical research company’s stock worth $2,088,000 after purchasing an additional 1,100 shares in the last quarter. E. Ohman J or Asset Management AB bought a new stake in Charles River Laboratories International during the third quarter valued at approximately $158,000. Assenagon Asset Management S.A. increased its holdings in shares of Charles River Laboratories International by 152.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 49,030 shares of the medical research company’s stock worth $9,657,000 after buying an additional 29,621 shares during the last quarter. Riverwater Partners LLC increased its holdings in shares of Charles River Laboratories International by 2.3% in the 3rd quarter. Riverwater Partners LLC now owns 5,643 shares of the medical research company’s stock worth $1,089,000 after buying an additional 126 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $83,800,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Down 0.3 %

NYSE CRL opened at $182.12 on Monday. The business’s 50-day moving average is $195.84 and its 200 day moving average is $211.08. The stock has a market capitalization of $9.38 billion, a PE ratio of 21.43, a PEG ratio of 5.11 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has authorized a share repurchase plan on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts recently commented on CRL shares. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. CLSA assumed coverage on Charles River Laboratories International in a research report on Wednesday, October 23rd. They issued an “underperform” rating and a $167.00 target price for the company. Barclays reduced their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Finally, Evercore ISI lowered shares of Charles River Laboratories International from an “outperform” rating to an “inline” rating and reduced their target price for the company from $225.00 to $190.00 in a report on Monday, October 7th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $209.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).